Archer-Daniels-Midland ADM
Consumer Defensive · Agricultural Farm Products · Synthos Deep Dive · 2026-07-03
The Overview
ADM is one of the world's biggest middlemen for food and crops — it buys grain and oilseeds from farmers, crushes and processes them into cooking oils, sweeteners, animal feed, ethanol, and food ingredients, and sells them worldwide. It's a 120-year-old company that pays a steady dividend (about 2.7% a year).
Is the stock cheap or expensive? Cheap-looking, but for a reason. It trades at less than 8× its free cash flow, which sounds like a bargain. The catch: ADM's profits swing wildly with commodity prices and government fuel rules, and profits recently fell hard (earnings per share dropped from about $7.70 in 2022 to $2.23 in 2025). So the "cheap" price reflects a business that isn't growing and can't be counted on year to year.
Our verdict is Watch — not a buy, not a sell. It sits right around what we think it's worth.
Here's what our three scores mean in everyday terms:
- Downside Risk 5/10 (middle of the road). The stock is steady (it doesn't jump around like a tech name) and it's cheap on cash flow, but it carries real debt and its profits are unpredictable.
- Growth Quality 3/10 (weak). Sales are actually shrinking, profits are thin (it keeps barely over a penny of each sales dollar), and it earns low returns on the money it invests.
- Exponential Potential 2/10 (very low). This is a big, mature, slow business. Don't expect it to multiply your money.
The one big worry: ADM's earnings depend on "crush spreads" (the profit from turning soybeans into oil and meal) and ethanol margins, which can collapse in a bad year. The cheap-looking price is measured against a good cash-flow year.
Putting a number on it: our fair-value estimate is $78 against a current price of $81.54 — consistent with our call to stay away or wait for a better setup.
Our summary metrics
Low beta (0.60) & cheap on FCF (7.7× P/FCF), but deep-cyclical earnings, 2.6× net-debt/EBITDA, 34× depressed trailing EPS.
Revenue shrinking (-6% FY25), thin ~5% forward EPS CAGR off a trough, 5.8% gross margin, sub-5% ROE — a low-return commodity processor.
No acceleration and no TAM headroom — a mature $37B ag-merchant levered to crush/ethanol spreads, not an exponential.
What does “fair value” mean?
Fair value is Synthos’s estimate of what one share is worth today, based on our model of the company’s future cash generation and the risks to it. It is not a price target or a prediction of where the stock trades next quarter — it’s the price where we think risk and reward are balanced. Above it, you’re paying for outcomes better than our base case; below it, the market is offering a margin of safety.
The model’s inputs and weightings are proprietary — they’re the product. What we publish is the output, plus an independent, public-math cross-check further down the page (“Check our number”) so you can judge it for yourself.
What do the 5 tiers mean? (Core · Tactical · Watch · Hold · Avoid)
Exponential Potential
No acceleration and no TAM headroom — a mature $37B ag-merchant levered to crush/ethanol spreads, not an exponential.
What could take this further than the base case — and where the market may be underpricing it. Full forward-growth and acceleration math in Deeper analysis, §4 below.
Deeper analysis
Technicals, fundamentals, valuation, and the full expert-claim evidence panel — the detail behind the numbers above.
Reference table
| Street consensus | $75.25 (high $95 / low $58; 12 Buy · 21 Hold · 3 Sell → Hold) — context, not our anchor |
| Valuation | 34× trailing (trough) EPS · ~16.5× FY26E · ~14× FY27E · EV/S 0.58× · EV/EBITDA 12.1× · P/FCF 7.7× |
| Technicals | Neutral — $76.79, −8.7% off 52-wk high, above 200-DMA but below 50-DMA, RSI 41, +41% 12-mo (SPY +21%) |
| Conviction | Low — 1 net-bullish voice (Brent Johnson, macro pair-trade), 1 reconciled claim; verdict is fundamentals/quant-driven |
| Position sizing | Not a flagship holding; 0% core, a value/income watch item only |
What the experts actually said 1 traceable claims on ADM · showing the highest-conviction voices
“Long ag merchants (ADM, Bunge) / short consumer discretionary (XLY): food/energy inflation cuts discretionary spending; incremental-return trade, wait for pullback.”
Every claim reconciles to a real claim_id in the Synthos knowledge base — this is the evidence the verdict is built on, not vibes. Management (the company itself) is shown but half-weighted; one cautionary voice is included on purpose.
Price & moving averages 12 months · 50 & 200-day averages · 52-week range
Solid line = price · dashed line = 50-day average · dotted line = 200-day average · the two thin horizontal lines mark the 52-week high and low. Price above both averages is an uptrend.
Data summary: last close $81.54, 2% above the 50-day average ($80), 14% above the 200-day average ($71) — an uptrend. 7% below the 52-week high of $87, 46% above the 52-week low of $56.
Bollinger Bands 20-day average ± 2 standard deviations
The shaded band widens when the stock gets more volatile. Riding the upper edge = strong momentum (sometimes stretched); the lower edge = weak / potentially oversold.
Data summary: price $81.54 is currently inside the band (band $77–$83).
RSI (14) momentum gauge · 0–100
Above 70 (overbought zone, shaded) = overbought, below 30 (oversold zone, shaded) = oversold. Currently 54.
MACD 12 / 26 / 9 · trend & momentum
The MACD line crossing above the signal line (bars flip to the up color) = momentum turning up; crossing below (bars flip to the down color) = turning down. Bar height = the size of that gap.
Data summary: MACD is currently above its signal line by 0.02, positive momentum.
Relative performance vs S&P 500 & its sector (XLP (sector)), set to 100 a year ago
Solid = ADM · dashed = S&P 500 · dotted = XLP (sector). A rising line means it is beating that benchmark — the sector line shows whether it is a leader or laggard within its own group.
Forward revenue & earnings actual → estimate · "FY" = fiscal year, "E" = estimate
Darker bars = actual results, brighter = analyst estimates. Taller bars to the right = expected growth.
Key stats an RIA wants
1. What it is
Archer-Daniels-Midland (NYSE: ADM), founded 1902 and headquartered in Chicago, is one of the "ABCD" global agricultural-commodity merchants. It sources, transports, stores, processes and distributes crops — oilseeds, corn, wheat — turning them into vegetable oils, protein meal, sweeteners, starches, ethanol, flour, and specialty food/feed ingredients. Fiscal year ends December 31. CEO Juan Luciano (also Chair).
Three reporting segments (FY2025 revenue, from filings):
- Ag Services & Oilseeds — $61.6B (77%): the core trading/origination + oilseed crushing engine (soybeans → oil + meal). Includes the Wilmar equity stake. Most cyclical; most exposed to crush spreads and global trade flows.
- Carbohydrate Solutions — $10.7B (13%): corn wet/dry milling → sweeteners, starches, and ethanol (Vantage Corn Processors). Levered to U.S. biofuels policy and ethanol margins.
- Nutrition — $7.5B (9%): the higher-margin, "growth" segment — flavors, proteins, emulsifiers, probiotics, animal nutrition. Has struggled (Decatur East plant outage) but is recovering.
Revenue by geography (FY2025, from filings): United States $31.2B (39%) · Switzerland $17.8B (trading hub) · Cayman Islands $6.1B · "Other Foreign" $15.2B · Brazil $3.4B · Mexico $2.7B · UK $2.1B · Canada $1.8B. This is a genuinely global commodity flow, not a US-domestic story — the Switzerland/Cayman lines are trading-desk routing, not end-demand.
2. The expert thesis (traceable)
Expert coverage in the Synthos KB is minimal: 1 total claim, 1 net-bullish voice, net conviction +0.3. This is a fundamentals-and-quant-driven verdict, not a conviction call. There is no broad expert panel behind ADM the way there is behind a megacap — say so plainly.
The single traceable claim is a macro pair-trade, not a company deep-dive:
- Brent Johnson (
brent_johnson-x3eUAWjvXl0:6dd3ea64c1, bullish, conviction 45, skill 0.7, dated 2026-04-12): long ag merchants (ADM, Bunge) / short consumer discretionary (XLY) — the thesis is that food/energy inflation squeezes discretionary spending, so grain merchants are a relative-value inflation hedge. Explicitly framed as "an incremental-return trade — wait for a pullback."
Read this honestly: it is a relative macro trade (own ag merchants versus discretionary), at moderate conviction, from one voice. It does not assert ADM is a great standalone business or a compounder. It is a weak positive signal, and we weight it as such. Everything else in this note is our own fundamental and quantitative work.
3. Synthos scores & the Bull / Base / Bear cases
The one-glance judgment — three scores, 0–10, each anchored to real metrics (not probabilities we can't honestly calibrate):
| Score | 0–10 | The read |
|---|---|---|
| Downside Risk (lower = safer) | 5 · Moderate | Low beta (0.60), cheap on FCF (7.7× P/FCF, 13% FCF yield), and a ~2.7% dividend cushion the downside; but earnings are deep-cyclical (EPS $7.72→$2.23 in three years), net-debt/EBITDA is 2.6×, and the 34× trailing multiple is on trough earnings. Roughly market-average risk. |
| Growth Quality | 3 · Weak | Revenue fell 6% in FY25 (and is below FY2021); ~5% forward EPS CAGR is a rebound off a trough, not secular growth; gross margin 5.8%, net margin 1.3%, ROE 4.8%, ROIC 2.9% — structurally low-return commodity processing. |
| Exponential Potential | 2 · Low | No acceleration (revenue decelerating/shrinking), no TAM headroom (mature global commodity flows), $37B cap. This is a value/cyclical name, categorically not an exponential. |
The three cases (our own scenario model — assumptions shown; each target is a ~12–18-month fair value). We deliberately do not attach probabilities: the base case is the expected path, so a weighted blend would just restate it with false precision. Instead the cases bound the range, and the scores above summarize them.
| Case | Key assumptions | Fair value |
|---|---|---|
| Bull | Biofuels tailwind sticks; crush + ethanol margins normalize up; Nutrition recovers. FY27E EPS reaches the high end ~$5.90; a mid-cycle re-rate to ~16× as earnings quality improves. | ~$96 (+25%) |
| Base (our anchor) | Management's raised FY26 guide (~$4.15–$4.70 adj EPS) roughly holds and FY27E lands near consensus ~$5.10–$5.50; a mature cyclical earns a ~14–15× normalized multiple; steady ~$4B FCF supports the dividend. | ~$78 (+2%) |
| Bear | Crush/ethanol spreads roll over, biofuels policy support fades, a trade/tariff shock hits export volumes; FY27E EPS slips toward ~$4 and the multiple stays low ~13×. | ~$55 (−28%) |
Synthos fair value = the base case, ~$78 (+2%), with the full $55–$96 span as the honest range. This sits essentially on top of the Street's $75.25 consensus (high $95 / low $58) — appropriate, because with almost no proprietary expert edge here, we defer more to the fundamental/consensus read than we would on a high-conviction name. The wide bear-to-bull span is the honest signature of a cyclical: the range is driven by spreads and policy, not by execution. This is a tracked call — the Forecaster Scorecard grades it once it matures.
4. Exponential Potential
Synthos separates compounders (durable high returns on capital) from exponentials (accelerating multi-baggers-from-here). ADM is neither — it is a mature, low-return cyclical:
- Forward growth: revenue essentially flat-to-down — FY25 $80.3B, consensus FY26E ~$86.4B, FY30E ~$85.8B. That's ~1% revenue CAGR over five years, i.e. no secular growth. EPS "grows" ~5%/yr only because FY25 was a trough ($2.23); consensus has EPS at $4.64 (FY26E) rising to ~$5.50 (FY28E) then fading back to $4.64 by FY30E — a rebound-then-plateau, not a ramp. (Note the outer-year estimates rest on just 1–3 analysts and should be read loosely.)
- Acceleration (2nd derivative): negative to flat. Revenue has fallen from $101.6B (FY22) → $93.9B → $85.5B → $80.3B (FY25). Earnings are recovering off a cyclical bottom, not accelerating structurally.
- Room to run: none in the multibagger sense. This is a mature player in mature global commodity markets; ADM's own volumes track world crop flows. There is no large, underpenetrated TAM to compound into.
- Reinvestment runway: capex ~$1.3–1.5B/yr (per guidance) into maintenance and select Nutrition/biosolutions capacity — but at ~3% ROIC, reinvestment doesn't create the value it would at a high-return franchise. Capital return (dividend + buyback) is the more sensible use, and management does both.
Exponential Potential: Low (2/10). Own ADM — if at all — for cheap cash flow, a covered dividend, and cyclical mean-reversion, not for growth. It is the polar opposite of a Synthos flagship next-exponential.
5. Financials (real numbers — FMP annual/quarterly)
- Revenue: FY25 $80.27B, −6.2% (FY24 $85.53B, itself −9% on FY23 $93.94B). Three straight years of top-line decline off the FY22 peak of $101.6B — driven mostly by lower commodity prices, not lost share, but a shrinking base nonetheless.
- Earnings: net income $1.078B FY25 (EPS $2.23), down from $1.80B (FY24) and $3.48B (FY23); the FY22 peak was $4.34B / $7.72 EPS. This is the key tell: ADM's earnings are deeply cyclical and just printed a trough.
- Quarterly trajectory: Q1'25 $0.61 → Q2 $0.45 → Q3 $0.22 → Q4'25 $0.94 → Q1'26 $0.62 GAAP EPS. Choppy, spread-driven, no clean trend. Q1'26 adjusted EPS was $0.71 (+1% YoY) — flattish, with a big ~$275M negative mark-to-market/timing drag on Ag Services from the strengthening margin environment (a timing artifact that should reverse).
- Margins (structurally thin): gross 5.8% TTM, EBITDA 4.8%, operating 1.5%, net 1.3% — commodity-processing economics. There is no premium margin here outside the small Nutrition segment.
- Returns on capital: ROE 4.8%, ROIC 2.9%, ROA 1.9% (TTM) — below cost of capital in a trough year. This is the crux of the low Growth-Quality score.
- Cash flow (the bright spot): operating CF $5.45B, capex −$1.25B, FCF $4.20B FY25 — a strong FCF year even as GAAP earnings troughed, thanks to a $2.76B working-capital release (inventory/receivables drawdown as prices fell). FCF yield ~13%, P/FCF 7.7×. Caveat: a chunk of that FCF is a one-off working-capital unwind that won't repeat every year — don't annualize $4.2B blindly.
- Balance sheet: total debt $8.4B, cash $1.0B, net debt $7.4B, net-debt/EBITDA 2.6×. Investment-grade and serviceable, but not a fortress; interest coverage is a modest ~2.0× on trough EBIT. (Note: FY25's much smaller reported current assets/liabilities vs FY24 reflect a balance-sheet reclassification in the filing; the debt and net-debt figures are the reliable read.)
6. Valuation — cheap, or a value trap?
ADM is the mirror image of a growth name: it looks cheap on cash flow and sales, expensive on trailing earnings — because earnings are at a cyclical low.
- On free cash flow: P/FCF 7.7×, FCF yield ~13% — genuinely cheap, if the FCF is sustainable (see the working-capital caveat above).
- On sales / EV: EV/Sales 0.58×, EV/EBITDA 12.1×, P/S 0.46× — low absolute multiples, appropriate for thin-margin commodity processing.
- On earnings: 34× trailing GAAP EPS looks expensive, but that's trough EPS. On forward estimates it's ~16.5× FY26E ($4.64) and ~14× FY27E (~$5.49) — reasonable for a cyclical mid-recovery, neither cheap nor rich.
- Dividend: ~2.7% yield, but the GAAP payout ratio is ~92% on trough earnings (far more comfortable ~45% against FCF). ADM is a Dividend King — the dividend is a real part of the total-return case and looks covered by FCF, thinner on earnings.
- Street targets (context): consensus $75.25, high $95, low $58; letter rating B-; grades 12 Buy / 21 Hold / 3 Sell → Hold. The Street is genuinely on the fence, and so are we.
Read: not a value trap yet — FCF and the dividend provide real support and the biofuels tailwind is a genuine near-term positive — but not a bargain that demands ownership either. Fairly priced. A Watch.
7. Technicals (computed from EOD price history)
- Trend: mixed. $76.79 sits above the 200-DMA ($67.43) but below the 50-DMA ($77.80) — a longer-term uptrend that has stalled short-term.
- Location: −8.7% off the 52-week high ($84.11), +43% off the 52-week low ($53.54); max drawdown from peak −21.8% (a reminder of the cyclicality).
- Momentum: RSI(14) 41 — soft, below the neutral 50 line but not oversold. MACD −0.60 (mildly negative) — near-term momentum has rolled over.
- Relative strength: ADM +41% 12-mo vs SPY +20.6% and QQQ +30.3% — strong trailing outperformance (the cyclical recovery rally), but +6% 3-mo lags SPY +14% and QQQ +22% — the leadership has cooled off recently.
- Read: technicals are neutral — a name that ran hard off the low and is now consolidating just below its 50-DMA. No urgent entry signal; a reclaim of the 50-DMA (~$78) would firm up the short-term trend, while a break of the 200-DMA (~$67) would be a warning.
8. Moat & competitive position
ADM's moat is scale and logistics, not brand or technology. Its edge is a global network of grain elevators, crush plants, ports, rail, and a trading desk that few can replicate — the classic ABCD oligopoly (ADM, Bunge, Cargill, Louis Dreyfus). But it's a thin moat: the products are commodities, pricing power is minimal (5.8% gross margin), and profits are dictated by crush spreads, ethanol margins, and weather/trade flows that ADM does not control. The Nutrition segment is the attempt to build a higher-margin, stickier ingredients business — strategically sensible, but still small (9% of revenue) and has underdelivered.
Peer set (FMP; note it's a mixed "consumer defensive" basket, not pure ag-merchants): direct comp Bunge Global (BG) $20.7B is the truest peer (the other big listed crusher, now merged with Viterra). The rest are packaged-food/staples names — Tyson (TSN) $21.0B, General Mills (GIS) $20.1B, Hershey (HSY) $36.9B, Kellanova (K) $29.0B, Kraft Heinz (KHC) $30.1B, Kimberly-Clark (KMB) $38.1B, Church & Dwight (CHD) $23.4B, Kenvue (KVUE) $38.1B, JBS $27.2B — different (branded, higher-margin) businesses. Against BG, ADM is the larger, more diversified merchant; against the branded staples, ADM is lower-margin and more cyclical but cheaper on cash flow.
9. Management, capital allocation & guidance
- Capital allocation: shareholder-friendly and disciplined on capex. FY25 returned ~$1.0B in dividends (a Dividend King, decades of increases) and has bought back stock in prior years (−$2.3B FY24, −$2.7B FY23; buyback paused in FY25 to preserve cash in the trough). Capex held to ~$1.25B FY25, guided $1.3–1.5B FY26. At sub-3% ROIC, prioritizing capital return over reinvestment is the correct call.
- Insider activity: the most recent filings (2026-07-01) are all routine director stock-unit awards (grants, not open-market buys or sells) — no signal either way. No cluster of alarming discretionary selling in the sampled window.
- Management's own guidance (half-weighted — their own book): ADM's Q1'26 earnings release (SEC 8-K, filed 2026-05-05) is a real earnings release and management raised full-year 2026 adjusted EPS guidance to ~$4.15–$4.70, up from $3.60–$4.25. In CEO Juan Luciano's words, the raise reflects "U.S. biofuels policy clarity now providing a stable regulatory framework" — specifically the finalization of the 2026 and 2027 Renewable Volume Obligations (RVO) under the Renewable Fuels Standard in March 2026, which lifts expected earnings in the crushing and ethanol businesses. Capex is guided to $1.3–1.5B. Management explicitly flags external risks it's watching: consumer trends, energy costs, supply-chain dislocations, ethanol developments, and global trade/tariff conditions. Treat as management's self-interested framing (half-weight); note this is adjusted, non-GAAP EPS. It is, however, a genuine positive: policy clarity is a real tailwind and the guide went up, not down.
10. Catalysts & what to watch
- Next earnings: 2026-08-04 (Q2'26; Street EPS $1.34, revenue ~$22.8B). Watch crush margins and the mark-to-market reversal — Q1'26 carried a ~$275M negative timing drag that should swing back as spreads are realized.
- U.S. biofuels / RVO policy: the single biggest near-term earnings swing factor. The March-2026 RVO finalization is the tailwind behind the guidance raise; any policy reversal cuts the other way.
- Crush & ethanol spreads: the core earnings driver — track soybean crush margins and ethanol margins directly.
- Nutrition recovery: Decatur East plant ramp and Flavors momentum — the path to higher-quality, less-cyclical earnings.
- Global trade / tariffs: ADM is an export machine (soybeans/sorghum to China, corn exports); tariff or trade-flow shocks hit volumes directly.
Thesis tripwires (what would change the call): a rollover in crush/ethanol spreads back toward FY24–25 lows; a biofuels-policy reversal; FCF falling well below the dividend on a normalized (ex-working-capital) basis; or a dividend-coverage scare. Conversely, a durable multi-quarter earnings recovery with sustained FCF could move this from Watch toward Buy — Tactical.
11. Key risks
- Deep cyclicality (structural): earnings swing 3×+ peak-to-trough ($7.72 → $2.23 EPS in three years) on spreads ADM doesn't control. The "cheap" valuation is measured against a strong FCF year.
- Policy dependence: a meaningful slice of the FY26 earnings-improvement story rests on U.S. biofuels/RVO policy staying supportive — a political variable.
- Leverage into a downturn: net-debt/EBITDA 2.6× and ~2.0× interest coverage on trough EBIT leave less cushion than the low beta implies if a bad crush year hits.
- Working-capital FCF is lumpy: FY25's $4.2B FCF was flattered by a $2.76B working-capital release as commodity prices fell; a price rebound reverses that, so don't extrapolate the 13% FCF yield naively.
- Low returns on capital / value-trap risk: sub-3% ROIC means ADM destroys value if it over-reinvests; the stock can stay cheap for years.
- Thin conviction / no expert edge: only 1 KB claim (a macro pair-trade). We have no proprietary informational advantage here — the call rests on public fundamentals.
- Accounting/segment complexity: heavy use of mark-to-market and non-GAAP "adjusted" figures; a prior accounting-review episode at ADM is a reminder to weight GAAP.
12. Verdict, position sizing & monitoring
Watch. ADM is a cheap-on-cash-flow, dividend-paying global grain merchant priced almost exactly at our ~$78 base-case fair value (+2%). The near-term setup has a genuine positive — management raised FY26 adjusted-EPS guidance on U.S. biofuels-policy clarity, and FCF (7.7× P/FCF, ~13% yield) plus a Dividend-King payout provide real support. But the business is deeply cyclical, revenue is shrinking, returns on capital are below cost of capital, and expert conviction is minimal (a single macro pair-trade claim). There is upside in a mid-cycle re-rate (bull ~$96) and real downside in a spread/policy rollover (bear ~$55) — a wide cyclical range with the base case landing right on the Street. That combination is a hold-and-monitor, not a buy.
- Sizing: not a flagship holding — 0% core. For an income/deep-value sleeve, ADM is a defensible watch item; add only on a pullback toward the low-$60s (nearer the 200-DMA and the bear case) where the risk/reward tilts, exactly as the one bullish voice (Brent Johnson) advises — "wait for a pullback."
- Monitoring: re-underwrite on the tripwires in §10; formal re-score each earnings print, starting 2026-08-04. This verdict is logged as a tracked Synthos call as of 2026-07-03 at $76.79.
- Single biggest risk: deep cyclicality — crush and ethanol spreads (and the biofuels policy behind them) drive the earnings, and the cheap headline is measured against a good year.
Provenance & disclosures
- Traceability: 1 KB claim, breadth 1, top skill 0.7 (Brent Johnson), last claim 2026-04-12 — reconciled to a real
claim_id(cited inline). Fabricated conviction is structurally impossible (claim-ID reconciliation). Expert coverage is thin; this is explicitly a fundamentals/quant-driven verdict. - Data as-of: fundamentals 2026-03-31 (Q1'26) · estimates & prices 2026-07-02/03 · expert claim 2026-04-12. Forward figures are analyst consensus (FMP) or management guidance, labeled as estimates.
- Management caveat: ADM's FY26 adjusted-EPS guidance is management's own, non-GAAP framing, half-weighted by design.
- Not investment advice. Independent research, educational and informational only, never personalized. Hypothetical/forward figures are labeled; the only performance numbers Synthos will headline are the live, real-money Flagship's.
- Version: 2026-07-03. Prior versions available via the deep-dive version dropdown ("based on the info at the time").